NCT02550639View on ClinicalTrials.gov

Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2018

Study Completion Date

October 31, 2018

Conditions
CMV InfectionKidney Transplantation
Interventions
OTHER

BIOMARKER- elispot test

ELISPOT TEST

Trial Locations (5)

Unknown

Hôpital Erasme- Cliniques Universitaires de Bruxelles,, Brussels

Hospital Clinic i Provincial, Barcelona

Hospital Universitario Miguel Servet, Zaragoza

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

08035

Hospital Universitari de la Vall d'Hebrón, Barcelona

All Listed Sponsors
lead

ORIOL BESTARD

OTHER

NCT02550639 - Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant | Biotech Hunter | Biotech Hunter